Primary Aldosteronism

1
Pipeline Programs
4
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
CIN-107 2 mg dosingPhase 21 trial
Active Trials
NCT04605549Completed15Est. Oct 2024
DS
Daiichi SankyoChina - Shanghai
1 program
CS-3150N/A1 trial
Active Trials
NCT02885662Completed44Est. Jul 2017
Novartis
NovartisBASEL, Switzerland
1 program
captopril testN/A1 trial
Active Trials
NCT00917345Unknown150Est. May 2009

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AstraZenecaCIN-107 2 mg dosing
Daiichi SankyoCS-3150
Novartiscaptopril test

Clinical Trials (3)

Total enrollment: 209 patients across 3 trials

NCT04605549AstraZenecaCIN-107 2 mg dosing

A Study of CIN-107 in Adults With Primary Aldosteronism

Start: Mar 2021Est. completion: Oct 202415 patients
Phase 2Completed
NCT02885662Daiichi SankyoCS-3150

Study of CS-3150 in Patients With Primary Aldosteronism

Start: Sep 2016Est. completion: Jul 201744 patients
N/ACompleted
NCT00917345Novartiscaptopril test

Diagnosis of Primary Aldosteronism: Comparison of Post Captopril Active Renin Concentration and Plasma Renin Activity

Start: Jan 2008Est. completion: May 2009150 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 companies competing in this space